25 XP   0   0   10

RTA Laboratuvarlari Biyolojik
Buy, Hold or Sell?

Let's analyse RTA Laboratuvarlari Biyolojik together

PenkeI guess you are interested in RTA Laboratuvarlari Biyolojik. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of RTA Laboratuvarlari Biyolojik. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about RTA Laboratuvarlari Biyolojik

I send you an email if I find something interesting about RTA Laboratuvarlari Biyolojik.

Quick analysis of RTA Laboratuvarlari Biyolojik (30 sec.)










What can you expect buying and holding a share of RTA Laboratuvarlari Biyolojik? (30 sec.)

How much money do you get?

How much money do you get?
₺0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
₺6.33
Expected worth in 1 year
₺17.91
How sure are you?
100.0%

+ What do you gain per year?

Total Gains per Share
₺11.58
Return On Investment
92.1%

For what price can you sell your share?

Current Price per Share
₺12.58
Expected price per share
₺9.91 - ₺13.69
How sure are you?
50%

1. Valuation of RTA Laboratuvarlari Biyolojik (5 min.)




Live pricePrice per Share (EOD)

₺12.58

Intrinsic Value Per Share

₺-14.03 - ₺-5.05

Total Value Per Share

₺-7.70 - ₺1.28

2. Growth of RTA Laboratuvarlari Biyolojik (5 min.)




Is RTA Laboratuvarlari Biyolojik growing?

Current yearPrevious yearGrowGrow %
How rich?$19.6m$10.6m$9m45.8%

How much money is RTA Laboratuvarlari Biyolojik making?

Current yearPrevious yearGrowGrow %
Making money$8.7m$3.5m$5.1m59.3%
Net Profit Margin326.8%29.8%--

How much money comes from the company's main activities?

3. Financial Health of RTA Laboratuvarlari Biyolojik (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#583 / 998

Most Revenue
#411 / 998

Most Profit
#84 / 998

What can you expect buying and holding a share of RTA Laboratuvarlari Biyolojik? (5 min.)

Welcome investor! RTA Laboratuvarlari Biyolojik's management wants to use your money to grow the business. In return you get a share of RTA Laboratuvarlari Biyolojik.

What can you expect buying and holding a share of RTA Laboratuvarlari Biyolojik?

First you should know what it really means to hold a share of RTA Laboratuvarlari Biyolojik. And how you can make/lose money.

Speculation

The Price per Share of RTA Laboratuvarlari Biyolojik is ₺12.58. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of RTA Laboratuvarlari Biyolojik.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in RTA Laboratuvarlari Biyolojik, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ₺6.33. Based on the TTM, the Book Value Change Per Share is ₺2.90 per quarter. Based on the YOY, the Book Value Change Per Share is ₺1.75 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ₺0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of RTA Laboratuvarlari Biyolojik.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps0.090.7%0.090.7%0.040.3%0.030.2%0.020.1%
Usd Book Value Change Per Share0.090.7%0.090.7%0.050.4%0.040.3%0.020.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.090.7%0.090.7%0.050.4%0.040.3%0.020.2%
Usd Price Per Share0.40-0.40-0.69-0.43-0.32-
Price to Earnings Ratio4.62-4.62-19.34-41.05-83.46-
Price-to-Total Gains Ratio4.49-4.49-12.62-24.83-67.52-
Price to Book Ratio2.05-2.05-6.45-6.45-10.36-
Price-to-Total Gains Ratio4.49-4.49-12.62-24.83-67.52-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.391238
Number of shares2555
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.090.04
Usd Total Gains Per Share0.090.04
Gains per Quarter (2555 shares)230.0491.93
Gains per Year (2555 shares)920.17367.74
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
109209100368358
20184018300735726
3027612750011031094
4036813670014711462
5046014590018391830
6055215510022062198
7064416430025742566
8073617350029422934
9082828270033103302
10092029190036773670

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%9.00.01.090.0%9.00.04.069.2%
Book Value Change Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%12.01.00.092.3%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.010.00.0%3.00.010.023.1%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%13.00.00.0100.0%

Fundamentals of RTA Laboratuvarlari Biyolojik

About RTA Laboratuvarlari Biyolojik

RTA Laboratuvarlari Biyolojik Urunler Ilac ve Makine Sanayi Ticaret A.S. engages in the research, development, and production of microbiology and molecular biology products in Turkey. It offers microbiology products, including petri dish, tube and bottle, chromogenic media, blood culture bottle, tuberculosis diagnostic, rapid test, microbiological stain, hygislide, surcheck media, membrane, and swab products; and molecular biology products, such as nucleic acid isolation kits, real time PCR kits, and voltran viral load detection systems. The company was incorporated in 1996 and is based in Kocaeli, Turkey.

Fundamental data was last updated by Penke on 2024-05-19 19:34:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is very efficient in making profit.
Using its investors money, the company is very efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is cheap.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of RTA Laboratuvarlari Biyolojik.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit RTA Laboratuvarlari Biyolojik earns for each ₤1 of revenue.

  • Above 10% is considered healthy but always compare RTA Laboratuvarlari Biyolojik to the Biotechnology industry mean.
  • A Net Profit Margin of 326.8% means that ₤3.27 for each ₤1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of RTA Laboratuvarlari Biyolojik:

  • The MRQ is 326.8%. The company is making a huge profit. +2
  • The TTM is 326.8%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ326.8%TTM326.8%0.0%
TTM326.8%YOY29.8%+297.0%
TTM326.8%5Y82.5%+244.3%
5Y82.5%10Y47.5%+34.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ326.8%-171.8%+498.6%
TTM326.8%-211.9%+538.7%
YOY29.8%-263.3%+293.1%
5Y82.5%-414.0%+496.5%
10Y47.5%-552.3%+599.8%
1.1.2. Return on Assets

Shows how efficient RTA Laboratuvarlari Biyolojik is using its assets to generate profit.

  • Above 5% is considered healthy but always compare RTA Laboratuvarlari Biyolojik to the Biotechnology industry mean.
  • 38.0% Return on Assets means that RTA Laboratuvarlari Biyolojik generated ₤0.38 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of RTA Laboratuvarlari Biyolojik:

  • The MRQ is 38.0%. Using its assets, the company is very efficient in making profit. +2
  • The TTM is 38.0%. Using its assets, the company is very efficient in making profit. +2
Trends
Current periodCompared to+/- 
MRQ38.0%TTM38.0%0.0%
TTM38.0%YOY20.7%+17.3%
TTM38.0%5Y17.6%+20.4%
5Y17.6%10Y12.3%+5.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ38.0%-11.9%+49.9%
TTM38.0%-11.5%+49.5%
YOY20.7%-10.9%+31.6%
5Y17.6%-13.1%+30.7%
10Y12.3%-14.4%+26.7%
1.1.3. Return on Equity

Shows how efficient RTA Laboratuvarlari Biyolojik is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare RTA Laboratuvarlari Biyolojik to the Biotechnology industry mean.
  • 47.3% Return on Equity means RTA Laboratuvarlari Biyolojik generated ₤0.47 for each ₤1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of RTA Laboratuvarlari Biyolojik:

  • The MRQ is 47.3%. Using its investors money, the company is very efficient in making profit. +2
  • The TTM is 47.3%. Using its investors money, the company is very efficient in making profit. +2
Trends
Current periodCompared to+/- 
MRQ47.3%TTM47.3%0.0%
TTM47.3%YOY36.6%+10.7%
TTM47.3%5Y26.1%+21.2%
5Y26.1%10Y17.5%+8.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ47.3%-15.3%+62.6%
TTM47.3%-14.6%+61.9%
YOY36.6%-13.6%+50.2%
5Y26.1%-17.7%+43.8%
10Y17.5%-19.2%+36.7%

1.2. Operating Efficiency of RTA Laboratuvarlari Biyolojik.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient RTA Laboratuvarlari Biyolojik is operating .

  • Measures how much profit RTA Laboratuvarlari Biyolojik makes for each ₤1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare RTA Laboratuvarlari Biyolojik to the Biotechnology industry mean.
  • An Operating Margin of -9.1% means the company generated ₤-0.09  for each ₤1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of RTA Laboratuvarlari Biyolojik:

  • The MRQ is -9.1%. The company is operating very inefficient. -2
  • The TTM is -9.1%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-9.1%TTM-9.1%0.0%
TTM-9.1%YOY24.7%-33.7%
TTM-9.1%5Y-5.3%-3.7%
5Y-5.3%10Y3.6%-8.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-9.1%-336.0%+326.9%
TTM-9.1%-224.0%+214.9%
YOY24.7%-280.1%+304.8%
5Y-5.3%-412.2%+406.9%
10Y3.6%-521.7%+525.3%
1.2.2. Operating Ratio

Measures how efficient RTA Laboratuvarlari Biyolojik is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.69 means that the operating costs are ₤1.69 for each ₤1 in net sales.

Let's take a look of the Operating Ratio trends of RTA Laboratuvarlari Biyolojik:

  • The MRQ is 1.686. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.686. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.686TTM1.6860.000
TTM1.686YOY1.341+0.345
TTM1.6865Y1.673+0.013
5Y1.67310Y1.468+0.205
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.6863.005-1.319
TTM1.6863.247-1.561
YOY1.3413.619-2.278
5Y1.6735.262-3.589
10Y1.4686.874-5.406

1.3. Liquidity of RTA Laboratuvarlari Biyolojik.

1.3. Liquidity
1.3.1. Current Ratio

Measures if RTA Laboratuvarlari Biyolojik is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.39 means the company has ₤3.39 in assets for each ₤1 in short-term debts.

Let's take a look of the Current Ratio trends of RTA Laboratuvarlari Biyolojik:

  • The MRQ is 3.393. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.393. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.393TTM3.3930.000
TTM3.393YOY1.803+1.590
TTM3.3935Y3.263+0.130
5Y3.26310Y3.295-0.032
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.3933.805-0.412
TTM3.3934.158-0.765
YOY1.8035.252-3.449
5Y3.2636.087-2.824
10Y3.2956.434-3.139
1.3.2. Quick Ratio

Measures if RTA Laboratuvarlari Biyolojik is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare RTA Laboratuvarlari Biyolojik to the Biotechnology industry mean.
  • A Quick Ratio of 1.87 means the company can pay off ₤1.87 for each ₤1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of RTA Laboratuvarlari Biyolojik:

  • The MRQ is 1.871. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 1.871. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.871TTM1.8710.000
TTM1.871YOY0.535+1.336
TTM1.8715Y1.640+0.230
5Y1.64010Y1.400+0.241
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.8713.202-1.331
TTM1.8713.816-1.945
YOY0.5355.183-4.648
5Y1.6405.929-4.289
10Y1.4006.351-4.951

1.4. Solvency of RTA Laboratuvarlari Biyolojik.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of RTA Laboratuvarlari Biyolojik assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare RTA Laboratuvarlari Biyolojik to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.15 means that RTA Laboratuvarlari Biyolojik assets are financed with 14.5% credit (debt) and the remaining percentage (100% - 14.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of RTA Laboratuvarlari Biyolojik:

  • The MRQ is 0.145. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.145. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.145TTM0.1450.000
TTM0.145YOY0.379-0.233
TTM0.1455Y0.225-0.079
5Y0.22510Y0.220+0.004
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1450.344-0.199
TTM0.1450.342-0.197
YOY0.3790.279+0.100
5Y0.2250.366-0.141
10Y0.2200.380-0.160
1.4.2. Debt to Equity Ratio

Measures if RTA Laboratuvarlari Biyolojik is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare RTA Laboratuvarlari Biyolojik to the Biotechnology industry mean.
  • A Debt to Equity ratio of 18.1% means that company has ₤0.18 debt for each ₤1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of RTA Laboratuvarlari Biyolojik:

  • The MRQ is 0.181. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.181. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.181TTM0.1810.000
TTM0.181YOY0.669-0.488
TTM0.1815Y0.346-0.165
5Y0.34610Y0.315+0.031
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1810.398-0.217
TTM0.1810.415-0.234
YOY0.6690.353+0.316
5Y0.3460.446-0.100
10Y0.3150.470-0.155

2. Market Valuation of RTA Laboratuvarlari Biyolojik

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₤1 in earnings RTA Laboratuvarlari Biyolojik generates.

  • Above 15 is considered overpriced but always compare RTA Laboratuvarlari Biyolojik to the Biotechnology industry mean.
  • A PE ratio of 4.62 means the investor is paying ₤4.62 for every ₤1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of RTA Laboratuvarlari Biyolojik:

  • The EOD is 4.475. Based on the earnings, the company is cheap. +2
  • The MRQ is 4.621. Based on the earnings, the company is cheap. +2
  • The TTM is 4.621. Based on the earnings, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD4.475MRQ4.621-0.146
MRQ4.621TTM4.6210.000
TTM4.621YOY19.341-14.720
TTM4.6215Y41.045-36.424
5Y41.04510Y83.459-42.414
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD4.475-2.276+6.751
MRQ4.621-2.535+7.156
TTM4.621-2.723+7.344
YOY19.341-3.942+23.283
5Y41.045-6.316+47.361
10Y83.459-6.544+90.003
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of RTA Laboratuvarlari Biyolojik:

  • The EOD is -8.193. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -8.460. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -8.460. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-8.193MRQ-8.460+0.267
MRQ-8.460TTM-8.4600.000
TTM-8.460YOY47.129-55.589
TTM-8.4605Y-108.737+100.277
5Y-108.73710Y230.515-339.251
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-8.193-3.153-5.040
MRQ-8.460-3.270-5.190
TTM-8.460-3.527-4.933
YOY47.129-5.220+52.349
5Y-108.737-8.080-100.657
10Y230.515-8.650+239.165
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of RTA Laboratuvarlari Biyolojik is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.05 means the investor is paying ₤2.05 for each ₤1 in book value.

Let's take a look of the Price to Book Ratio trends of RTA Laboratuvarlari Biyolojik:

  • The EOD is 1.988. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.053. Based on the equity, the company is underpriced. +1
  • The TTM is 2.053. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.988MRQ2.053-0.065
MRQ2.053TTM2.0530.000
TTM2.053YOY6.450-4.397
TTM2.0535Y6.455-4.402
5Y6.45510Y10.363-3.908
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.9882.066-0.078
MRQ2.0532.029+0.024
TTM2.0532.065-0.012
YOY6.4502.688+3.762
5Y6.4553.688+2.767
10Y10.3634.088+6.275
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of RTA Laboratuvarlari Biyolojik compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--2.8952.8950%1.754+65%1.157+150%0.622+366%
Book Value Per Share--6.3276.3270%3.432+84%2.575+146%1.497+323%
Current Ratio--3.3933.3930%1.803+88%3.263+4%3.295+3%
Debt To Asset Ratio--0.1450.1450%0.379-62%0.225-35%0.220-34%
Debt To Equity Ratio--0.1810.1810%0.669-73%0.346-48%0.315-43%
Dividend Per Share----0%-0%-0%-0%
Eps--2.8112.8110%1.145+146%0.926+203%0.483+482%
Free Cash Flow Per Share---1.535-1.5350%0.470-427%-0.248-84%-0.114-93%
Free Cash Flow To Equity Per Share---1.505-1.5050%1.229-222%-0.005-100%0.022-6992%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%0.900+11%
Intrinsic Value_10Y_max---5.046--------
Intrinsic Value_10Y_min---14.031--------
Intrinsic Value_1Y_max---0.199--------
Intrinsic Value_1Y_min---0.645--------
Intrinsic Value_3Y_max---0.832--------
Intrinsic Value_3Y_min---2.609--------
Intrinsic Value_5Y_max---1.746--------
Intrinsic Value_5Y_min---5.292--------
Market Cap1258000000.000-3%1299000000.0001299000000.0000%2214000000.000-41%1389400000.000-7%1014202000.000+28%
Net Profit Margin--3.2683.2680%0.298+997%0.825+296%0.475+587%
Operating Margin---0.091-0.0910%0.247-137%-0.053-41%0.036-351%
Operating Ratio--1.6861.6860%1.341+26%1.673+1%1.468+15%
Pb Ratio1.988-3%2.0532.0530%6.450-68%6.455-68%10.363-80%
Pe Ratio4.475-3%4.6214.6210%19.341-76%41.045-89%83.459-94%
Price Per Share12.580-3%12.99012.9900%22.140-41%13.894-7%10.142+28%
Price To Free Cash Flow Ratio-8.193+3%-8.460-8.4600%47.129-118%-108.737+1185%230.515-104%
Price To Total Gains Ratio4.345-3%4.4874.4870%12.621-64%24.830-82%67.519-93%
Quick Ratio--1.8711.8710%0.535+250%1.640+14%1.400+34%
Return On Assets--0.3800.3800%0.207+83%0.176+116%0.123+210%
Return On Equity--0.4730.4730%0.366+29%0.261+81%0.175+170%
Total Gains Per Share--2.8952.8950%1.754+65%1.157+150%0.622+366%
Usd Book Value--19678206.72319678206.7230%10674586.046+84%8008479.736+146%4656296.590+323%
Usd Book Value Change Per Share--0.0900.0900%0.055+65%0.036+150%0.019+366%
Usd Book Value Per Share--0.1970.1970%0.107+84%0.080+146%0.047+323%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps--0.0870.0870%0.036+146%0.029+203%0.015+482%
Usd Free Cash Flow---4775379.902-4775379.9020%1460997.171-427%-770331.487-84%-355089.661-93%
Usd Free Cash Flow Per Share---0.048-0.0480%0.015-427%-0.008-84%-0.004-93%
Usd Free Cash Flow To Equity Per Share---0.047-0.0470%0.038-222%0.000-100%0.001-6992%
Usd Market Cap39123800.000-3%40398900.00040398900.0000%68855400.000-41%43210340.000-7%31541682.200+28%
Usd Price Per Share0.391-3%0.4040.4040%0.689-41%0.432-7%0.315+28%
Usd Profit--8742738.8878742738.8870%3560131.075+146%2870828.398+205%1498441.260+483%
Usd Revenue--2675408.2272675408.2270%11953025.035-78%4590661.048-42%2758849.642-3%
Usd Total Gains Per Share--0.0900.0900%0.055+65%0.036+150%0.019+366%
 EOD+3 -5MRQTTM+0 -0YOY+21 -125Y+20 -1310Y+24 -10

3.2. Fundamental Score

Let's check the fundamental score of RTA Laboratuvarlari Biyolojik based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-154.475
Price to Book Ratio (EOD)Between0-11.988
Net Profit Margin (MRQ)Greater than03.268
Operating Margin (MRQ)Greater than0-0.091
Quick Ratio (MRQ)Greater than11.871
Current Ratio (MRQ)Greater than13.393
Debt to Asset Ratio (MRQ)Less than10.145
Debt to Equity Ratio (MRQ)Less than10.181
Return on Equity (MRQ)Greater than0.150.473
Return on Assets (MRQ)Greater than0.050.380
Total8/10 (80.0%)

3.3. Technical Score

Let's check the technical score of RTA Laboratuvarlari Biyolojik based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5049.812
Ma 20Greater thanMa 5012.626
Ma 50Greater thanMa 10012.513
Ma 100Greater thanMa 20013.738
OpenGreater thanClose12.710
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2022-12-31. Currency in TRY. All numbers in thousands.

Summary
Total Assets740,213
Total Liabilities107,473
Total Stockholder Equity594,521
 As reported
Total Liabilities 107,473
Total Stockholder Equity+ 594,521
Total Assets = 740,213

Assets

Total Assets740,213
Total Current Assets300,531
Long-term Assets439,682
Total Current Assets
Cash And Cash Equivalents 31,363
Short-term Investments 118,082
Net Receivables 47,648
Inventory 27,249
Other Current Assets 30,309
Total Current Assets  (as reported)300,531
Total Current Assets  (calculated)254,650
+/- 45,881
Long-term Assets
Property Plant Equipment 53,680
Intangible Assets 449
Other Assets 11,663
Long-term Assets  (as reported)439,682
Long-term Assets  (calculated)65,792
+/- 373,890

Liabilities & Shareholders' Equity

Total Current Liabilities88,585
Long-term Liabilities18,888
Total Stockholder Equity594,521
Total Current Liabilities
Short Long Term Debt 67,076
Accounts payable 11,149
Other Current Liabilities 8,796
Total Current Liabilities  (as reported)88,585
Total Current Liabilities  (calculated)87,021
+/- 1,564
Long-term Liabilities
Long term Debt 1,577
Capital Lease Obligations Min Short Term Debt1,183
Other Liabilities 16,489
Long-term Liabilities  (as reported)18,888
Long-term Liabilities  (calculated)19,249
+/- 361
Total Stockholder Equity
Common Stock100,000
Retained Earnings 463,841
Other Stockholders Equity 8,865
Total Stockholder Equity (as reported)594,521
Total Stockholder Equity (calculated)572,706
+/- 21,815
Other
Capital Stock100,000
Common Stock Shares Outstanding 100,000
Net Debt 37,290
Net Invested Capital 663,174
Net Tangible Assets 594,072
Net Working Capital 212,336
Property Plant and Equipment Gross 71,209



Balance Sheet

Currency in TRY. All numbers in thousands.

 Trend2022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-31
> Total Assets 
16,857
16,604
20,450
29,352
49,042
61,614
60,893
63,092
66,052
98,160
256,525
552,404
740,213
740,213552,404256,52598,16066,05263,09260,89361,61449,04229,35220,45016,60416,857
   > Total Current Assets 
0
0
0
0
36,222
38,662
37,436
40,847
32,864
34,561
142,975
369,387
300,531
300,531369,387142,97534,56132,86440,84737,43638,66236,2220000
       Cash And Cash Equivalents 
5,472
2,913
2,745
3,246
18,570
15,736
13,790
15,124
6,141
12,379
15,662
157,539
31,363
31,363157,53915,66212,3796,14115,12413,79015,73618,5703,2462,7452,9135,472
       Short-term Investments 
0
0
0
0
0
0
1,735
1,697
51
0
917
5,863
118,082
118,0825,8639170511,6971,735000000
       Net Receivables 
4,575
4,649
7,204
5,501
7,847
9,364
9,872
14,865
18,515
16,310
73,833
103,661
47,648
47,648103,66173,83316,31018,51514,8659,8729,3647,8475,5017,2044,6494,575
       Other Current Assets 
512
628
863
808
1,419
2,742
2,053
1,390
3,984
2,763
21,661
41,830
30,309
30,30941,83021,6612,7633,9841,3902,0532,7421,419808863628512
   > Long-term Assets 
0
0
0
0
0
0
23,457
22,244
33,188
63,600
113,550
183,017
439,682
439,682183,017113,55063,60033,18822,24423,457000000
       Property Plant Equipment 
2,191
1,836
3,237
8,061
8,246
10,062
11,616
9,482
11,167
14,781
31,399
46,754
53,680
53,68046,75431,39914,78111,1679,48211,61610,0628,2468,0613,2371,8362,191
       Goodwill 
0
0
0
0
0
1,031
1,031
1,031
1,031
0
0
0
0
00001,0311,0311,0311,03100000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
28,193
0
0
0
00028,193000000000
       Intangible Assets 
357
1,047
1,127
808
680
158
53
1,011
687
477
760
564
449
4495647604776871,011531586808081,1271,047357
       Long-term Assets Other 
0
0
0
0
0
0
23,457
22,244
33,188
63,600
0
0
0
00063,60033,18822,24423,457000000
> Total Liabilities 
5,393
6,412
9,459
8,519
11,399
14,878
10,690
8,841
8,990
11,466
88,719
209,170
107,473
107,473209,17088,71911,4668,9908,84110,69014,87811,3998,5199,4596,4125,393
   > Total Current Liabilities 
4,987
6,062
8,963
7,043
9,725
9,831
9,278
8,264
6,625
7,808
82,514
204,880
88,585
88,585204,88082,5147,8086,6258,2649,2789,8319,7257,0438,9636,0624,987
       Short-term Debt 
0
0
0
0
254
3,470
1,321
1,595
637
6,109
0
0
0
0006,1096371,5951,3213,4702540000
       Short Long Term Debt 
0
0
0
0
254
3,470
1,321
1,595
637
6,109
21,910
55,121
67,076
67,07655,12121,9106,1096371,5951,3213,4702540000
       Accounts payable 
2,254
3,894
5,234
5,530
7,573
7,224
5,902
4,862
5,260
1,438
23,557
101,272
11,149
11,149101,27223,5571,4385,2604,8625,9027,2247,5735,5305,2343,8942,254
       Other Current Liabilities 
1,791
1,176
2,412
1,505
1,898
2,181
1,519
1,667
113
83
29,922
45,750
8,796
8,79645,75029,922831131,6671,5192,1811,8981,5052,4121,1761,791
   > Long-term Liabilities 
0
0
0
0
0
0
1,412
578
330
3,657
6,204
4,289
18,888
18,8884,2896,2043,6573305781,412000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
-254
-3,470
-1,319
-1,595
-637
-6,109
985
528
1,183
1,183528985-6,109-637-1,595-1,319-3,470-2540000
       Deferred Long Term Liability 
0
0
0
0
0
646
0
954
630
357
104
0
0
00104357630954064600000
> Total Stockholder Equity
11,848
10,991
11,875
20,833
36,726
45,922
49,922
54,171
57,912
86,628
150,275
312,674
594,521
594,521312,674150,27586,62857,91254,17149,92245,92236,72620,83311,87510,99111,848
   Common Stock
4,800
4,800
4,800
4,800
5,900
5,900
5,900
23,600
23,600
36,100
41,000
42,970
100,000
100,00042,97041,00036,10023,60023,6005,9005,9005,9004,8004,8004,8004,800
   Retained Earnings 
5,699
4,454
6,031
11,575
16,183
22,780
26,902
25,618
27,774
32,228
93,161
207,634
463,841
463,841207,63493,16132,22827,77425,61826,90222,78016,18311,5756,0314,4545,699
   Capital Surplus 0000000000000
   Treasury Stock000000-94000000
   Other Stockholders Equity 
0
0
0
0
2,516
5,115
5,087
4,952
8,161
18,230
9,183
9,192
8,865
8,8659,1929,18318,2308,1614,9525,0875,1152,5160000



Balance Sheet

Currency in TRY. All numbers in thousands.




Cash Flow

Currency in TRY. All numbers in thousands.




Income Statement

Currency in TRY. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue52,558
Cost of Revenue-40,946
Gross Profit11,61211,612
 
Operating Income (+$)
Gross Profit11,612
Operating Expense-67,490
Operating Income-14,932-55,877
 
Operating Expense (+$)
Research Development7,635
Selling General Administrative10,150
Selling And Marketing Expenses-
Operating Expense67,49017,785
 
Net Interest Income (+$)
Interest Income15,938
Interest Expense-15,472
Other Finance Cost-31,948
Net Interest Income-31,482
 
Pretax Income (+$)
Operating Income-14,932
Net Interest Income-31,482
Other Non-Operating Income Expenses-
Income Before Tax (EBT)262,488-14,932
EBIT - interestExpense = -15,472
249,437
264,909
Interest Expense15,472
Earnings Before Interest and Taxes (EBIT)-277,960
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax262,488
Tax Provision-13,112
Net Income From Continuing Ops249,376249,376
Net Income249,437
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-31,482
 

Technical Analysis of RTA Laboratuvarlari Biyolojik
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of RTA Laboratuvarlari Biyolojik. The general trend of RTA Laboratuvarlari Biyolojik is BEARISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine RTA Laboratuvarlari Biyolojik's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-57.1%) Bearish trend (57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of RTA Laboratuvarlari Biyolojik.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 13.40 < 13.57 < 13.69.

The bearish price targets are: 11.94 > 11.11 > 9.91.

Tweet this
RTA Laboratuvarlari Biyolojik Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of RTA Laboratuvarlari Biyolojik. The current mas is .

The long score for the Moving Averages is 3/14.
The longshort score for the Moving Averages is -8/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

RTA Laboratuvarlari Biyolojik Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of RTA Laboratuvarlari Biyolojik. The current macd is -0.05556316.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the RTA Laboratuvarlari Biyolojik price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for RTA Laboratuvarlari Biyolojik. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the RTA Laboratuvarlari Biyolojik price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
RTA Laboratuvarlari Biyolojik Daily Moving Average Convergence/Divergence (MACD) ChartRTA Laboratuvarlari Biyolojik Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of RTA Laboratuvarlari Biyolojik. The current adx is 15.73.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy RTA Laboratuvarlari Biyolojik shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
RTA Laboratuvarlari Biyolojik Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of RTA Laboratuvarlari Biyolojik. The current sar is 13.37.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
RTA Laboratuvarlari Biyolojik Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of RTA Laboratuvarlari Biyolojik. The current rsi is 49.81. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1